Home
Research
Atomic AI

Atomic AI

A specialized biotech platform that uses deep learning to map RNA structures for drug discovery—essential for high-end pharmaceutical R&D but inaccessible as a standalone software product.

Excellent for pharmaceutical teams identifying druggable RNA targets, but strictly an enterprise-level partnership play rather than a self-serve tool.

Biology Biotechnology Healthcare Machine Learning Scientific Discovery Medical Data Analysis Research

Analysis based on product data, pricing structure, traffic signals, and public user sentiment.

Visit Website

Share this tool

Facebook X

LinkedIn Reddit

WhatsApp Telegram

Who Should Use Atomic AI?

Typical users

Computational biologists, medicinal chemists, and R&D leads at large pharmaceutical firms or well-funded biotech startups.

Maturity fit

advanced

Choose this if…

You are targeting 'undruggable' diseases where protein-centric approaches have failed
Your priority is high-resolution 3D RNA structural prediction over 2D sequence analysis
You have the budget for a strategic R&D partnership rather than a software subscription

Skip this if…

You are an individual academic researcher looking for a self-serve or free tool
Your workflow is focused exclusively on protein folding (use AlphaFold instead)
You need an off-the-shelf SaaS product with immediate login access

About Atomic AI

Atomic AI is a biotechnology platform designed to unlock RNA as a therapeutic target. It combines proprietary wet-lab data generation with deep learning to predict how RNA folds into complex 3D shapes, identifying novel binding sites for small-molecule drugs.

Official profiles

X (Twitter) LinkedIn

What it actually does

The platform generates high-resolution structural models of RNA molecules to find 'pockets' where drugs can bind. It integrates high-throughput experimental chemical mapping with machine learning to accelerate the discovery of RNA-targeted medicines.

What makes it different

Unlike general AI models trained on public data, Atomic AI uses a closed-loop system where they generate their own proprietary experimental data to train models specifically for RNA. This focus addresses the unique flexibility and structural complexity of RNA that general-purpose tools often miss.

Atomic-level RNA 3D structure prediction Identification of novel druggable RNA motifs High-throughput chemical mapping (wet-lab integration) Small molecule screening for RNA targets Proprietary dataset generation for RNA-ligand interactions Custom RNA-based therapeutic design

Key Features

PARSE Platform

The core engine for high-throughput RNA structure exploration and data generation.

Deep Learning Engine

Predicts 3D atomic coordinates of RNA molecules without needing crystallization.

RNA-Targeted Small Molecule Discovery

Identifies specific sites where small molecules can modulate RNA function.

Proprietary RNA Data

Uses internal experimental results to refine AI accuracy beyond public datasets.

Multi-Disease Application

Capable of targeting oncology, neurology, and rare genetic disorders.

Wet-lab Feedback Loop

Validates AI-generated structural predictions with real-world biological testing.

Pricing

Popular

Enterprise Partnership

Custom

Full access to PARSE platform
Custom RNA target identification
Collaborative R&D with Atomic AI scientists
Proprietary data generation and validation

Pricing checked 4 months ago

Pricing guidance

Best plan for most users: The only path to access is through a strategic partnership or enterprise contract.

Free plan enough? No — there is no free tier or public-facing trial available.

Upgrade when:

When moving from target identification to lead optimization
When requiring proprietary wet-lab validation of AI predictions

Watch out for:

Access is gated by manual vetting
Requires significant internal computational biology expertise to manage the partnership

Premium enterprise positioning typical of high-tech biotech platforms.

Pros & Cons

Strengths

Superior RNA structural precision
By focusing exclusively on RNA, the platform handles the molecule's dynamic nature better than general structural biology tools.
Proprietary data advantage
The integration of a dedicated wet-lab means their models are trained on high-quality, relevant data that isn't available in the public domain.
Targets 'undruggable' pathways
Enables researchers to go after disease-relevant RNA that was previously considered too complex for small-molecule intervention.

Weaknesses

Not a self-serve tool
You cannot simply sign up and use the software; it requires a formal business partnership or enterprise agreement.

Affects: Small labs and independent researchers
High barrier to entry
The cost and infrastructure required for these types of partnerships are typically only feasible for large organizations.

Affects: Early-stage startups with limited funding
Narrow specialization
The platform is highly optimized for RNA; it is not a general-purpose drug discovery suite for all biological targets.

Affects: Teams needing a broad-spectrum discovery platform

Real User Sentiment

Highly respected within the scientific and venture capital communities for its technical foundation, though it lacks a traditional 'user' base that leaves public reviews.

Users tend to like

Technical rigor of the PARSE platform
Focus on RNA, a high-potential but difficult target
Strong leadership team with deep ML and biology expertise

Users commonly complain about

Lack of public access to the tool
Opaque pricing and partnership terms

Recurring tradeoffs

Users trade immediate software access for a deep, collaborative R&D relationship.

Happiest users

Large pharmaceutical companies looking to expand their pipeline into RNA-targeted therapeutics.

Often frustrated

Academic researchers or small-scale developers looking for an open-source or affordable RNA folding tool.

Use Cases

Oncology Research

Identifying RNA structures that drive tumor growth to develop new inhibitors.

Neurological Disorders

Targeting RNA involved in neurodegenerative diseases like Huntington's or ALS.

Rare Disease Discovery

Finding druggable sites on RNA for conditions with no known protein targets.

Small Molecule Screening

Using AI models to predict which chemical compounds will bind effectively to a specific RNA fold.

Structural Biology

Generating high-resolution 3D models of RNA to understand its biological function.

Frequently Asked Questions

How much does Atomic AI cost?

Atomic AI does not have public pricing. It operates on a B2B partnership model where costs are determined by the scope of the research project, the number of targets, and the level of wet-lab integration required. Expect enterprise-level investment.

Can I use Atomic AI for protein folding?

No. Atomic AI is specifically engineered for RNA structural prediction. For protein folding, tools like Google DeepMind's AlphaFold or Meta's ESMFold are the industry standards.

How does Atomic AI compare to Arrakis Therapeutics?

Both focus on RNA-targeted small molecules. However, Atomic AI leans more heavily into the 'AI-first' structural prediction and proprietary data generation (the PARSE platform), whereas Arrakis is a more traditional, albeit advanced, biotech firm with its own established drug pipeline.

Is there a free version for students or academics?

Currently, there is no public-facing free version or academic license for the PARSE platform. Academics typically rely on open-source tools like RosettaRNA or secondary structure predictors like ViennaRNA.

What kind of data does Atomic AI use?

Atomic AI uses a combination of public structural data and their own proprietary high-throughput chemical mapping data. This 'closed-loop' approach allows them to train models on RNA-specific interactions that are often missing from public databases like the PDB.

Does Atomic AI provide the drugs or just the targets?

Atomic AI is a platform for discovery. They identify the targets and help design the molecules, but the actual manufacturing and clinical trials are typically handled in collaboration with their pharmaceutical partners.

Why trust this page?

This evaluation combines product positioning, pricing analysis, traffic and market signals, and public user sentiment into a single decision-support page. Content is generated editorially — not copied from the vendor's website.

Funding & Company

Founded

2021

Stage

Series a

Total Raised

$42M

Latest Round

Series A (Jan 2023)

Notable Investors

Playground Global 8VC Greylock

Atomic AI has raised a total of $42 million across two rounds, a Seed round and a Series A. [6, 8] The most recent funding was a $35 million Series A in January 2023, led by Playground Global. [2, 15] This capital suggests strong investor confidence in its specialized approach to RNA drug discovery.

Full funding report high confidence

Market Signals & Traffic

Estimated visits, global rank, geography, traffic sources, monthly visit trends, and organic search keywords (Similarweb)—on a dedicated page built for depth and search.

Estimated visits: 7,445
Global rank: #2,572,116
Snapshot: Apr 2026
Traffic trend: Surging